Clinical Trial Detail

NCT ID NCT04196530
Title BDB001-102 Open Label Dose Escalation Combination w Atezolizumab
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Birdie Biopharmaceuticals HK Limited
Indications

Advanced Solid Tumor

Therapies

Atezolizumab + BDB001

Age Groups: adult senior

No variant requirements are available.